DRC Ebola total grows by 10; newly affected areas linked to Beni
The rate of Ebola cases in the Democratic Republic of the Congo (DRC) outbreak shows a slight decline, with Beni and Mandima still remaining as the main hot spots, according to a weekly outbreak and emergencies report from the World Health Organization (WHO) African regional office that covers cases through Aug 17.
Recent spread to South Kivu province and Pinga health zone in North Kivu province are linked to Beni, which officials have said continues to seed the virus to other areas.
The WHO said it is critical that local transmission in the newly affected areas is curbed with robust control measures, as was done recently in Goma, the capital of North Kivu province.
In other outbreak developments, the DRC confirmed 10 new cases, pushing the overall outbreak total to 2,909, according to the WHO's online Ebola dashboard today, which reflects cases reported as of Aug 18. Health officials are still investigating 301 suspected cases. The number of deaths remained at 1,934.
Aug 20 WHO African regional office weekly outbreak and emergencies report
WHO online Ebola dashboard
WHO: Flu activity still brisk in parts of Australia
Flu levels have peaked in most Southern Hemisphere countries, except for parts of Australia, the WHO said yesterday in its latest global flu update.
Australia's flu season started earlier than previous seasons. Though activity seems to have peaked in Southern Australia, Victoria, New South Wales, and Tasmania, so far Queensland's levels haven't peaked. H3N2 is the main strain, followed by influenza B.
In New Zealand, flu levels are dropping, but activity is still elevated, with both H3N2 and influenza B strains detected. In both countries, markers for severe infections such as hospitalizations and intensive care unit admissions have been low. Meanwhile, in temperate parts of South America, flu levels declined with all strains circulating except in Uruguay, which reported a slight uptick in 2009 H1N1 detections.
Elsewhere in the world, flu levels remained low except for Myanmar, where activity is still high, led by 2009 H1N1 and in Madagascar, which is experiencing a rise in influenza B illnesses.
Globally, influenza A made up 63.9% of detections reported for the week ending Aug 4. Of the subtyped influenza A strains, 61.1% were H3N2 and 38.9% H1N1.
Aug 19 WHO global flu update
NIAID awards $2.2 million for broadly protective flu patch vaccine candidate
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the developers of the MIMIX flu vaccine up to $2.2 million in funding yesterday.
Scientists from Vaxess Technologies, Inc. of Cambridge, Massachusetts, the maker of MIMIX, use smart release technology in the flu vaccine patch, designed to be worn for an extended period. Vaxess says the patch delivery system more closely replicates a natural flu infection and thus triggers a more protective immune response. The makers of the patch also say the vaccine will protect against both vaccine-included and drifted influenza strains.
"The MIMIX smart release patch has demonstrated to increase existing flu vaccine efficacy and advancing toward the creation of a universal flu vaccine quickly," said Vaxess vice president of policy and strategy, Livio Valenti in a Vaxess news release. "Moreover, the patch does not require refrigeration, is painless, and can be easily administered at home; additional benefits that will increase immunization rates here in the US and globally."
The NIAID funding will help launch the phase 1 trail of MIMIX.
Aug 19 Vaxess press release
FDA gives fast-track designation to Zika vaccine
Yesterday Moderna, Inc., also of Cambridge, announced that the US Food and Drug Administration (FDA) has granted "Fast Track" designation for its investigational Zika vaccine, mRNA-1893, currently being evaluated in a phase 1 study in healthy adults.
Fast Track designation helps expedite the review of vaccines and medications for unmet medical needs.
"Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need. Fast Track designation supports our belief in the clinical potential of mRNA-1893 and the importance of developing an effective vaccine that can be rapidly developed and deployed," said Tal Zaks, MD, PhD, chief medical officer at Moderna, in a company press release.
"Our Zika program is part of Moderna's broader commitment to improving global public health through developing mRNA vaccines to prevent the spread of infectious diseases."
In mouse studies, mRNA-1893 was protective against Zika in pregnancy. It contains an mRNA sequence encoding for the structural proteins of Zika virus and is designed to cause cells to secrete virus-like particles, Moderna said in the release.
Aug 19 Moderna press release